Vitiligo represents the most common cause of acquired skin, hair and oral depigmentation, affecting 0.5-1% of the population worldwide. It is clinically characterized by the appearance of disfiguring circumscribed skin macules following melanocyte destruction by autoreactive cytotoxic T lymphocytes. Patients affected by vitiligo usually show a poorer quality of life and are more likely to suffer from depressive symptoms, particularly evident in dark-skinned individuals. Although vitiligo is a non-fatal disease, exposure of affected skin to UV light increases the chance of skin irritation and predisposes to skin cancer. In addition, vitiligo has been associated to other rare systemic disorders due to presence of melanocytes in other body districts, such as in the eyes, auditory, nervous and cardiac tissues, where melanocytes are thought to have roles different from that played in the skin. Several pathogenetic models have been proposed to explain vitiligo onset and progression, but clinical and experimental findings point mainly to the autoimmune hypothesis as the most qualified one. In this context, it is of relevance the strong association of vitiligo with other autoimmune diseases, in particular with autoimmune thyroid disorders, such as Hashimoto thyroiditis and Graves’ disease. In this review, after a brief overview of vitiligo and its pathogenesis, we will describe the clinical association between vitiligo and autoimmune thyroid disorders and discuss the possible underlying molecular mechanism(s).

Vitiligo and autoimmune thyroid disorders / Baldini, Enke; Odorisio, Teresa; Sorrenti, Salvatore; Catania, Antonio; Tartaglia, Francesco; Carbotta, Giovanni; Pironi, Daniele; Rendina, Roberta; D'Armiento, Eleonora; Persechino, Severino; Ulisse, Salvatore. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - STAMPA. - 8:(2017). [10.3389/fendo.2017.00290]

Vitiligo and autoimmune thyroid disorders

Baldini, Enke;Sorrenti, Salvatore;Catania, Antonio;Tartaglia, Francesco;Carbotta, Giovanni;Pironi, Daniele;Rendina, Roberta;D'armiento, Eleonora;Persechino, Severino;Ulisse, Salvatore
2017

Abstract

Vitiligo represents the most common cause of acquired skin, hair and oral depigmentation, affecting 0.5-1% of the population worldwide. It is clinically characterized by the appearance of disfiguring circumscribed skin macules following melanocyte destruction by autoreactive cytotoxic T lymphocytes. Patients affected by vitiligo usually show a poorer quality of life and are more likely to suffer from depressive symptoms, particularly evident in dark-skinned individuals. Although vitiligo is a non-fatal disease, exposure of affected skin to UV light increases the chance of skin irritation and predisposes to skin cancer. In addition, vitiligo has been associated to other rare systemic disorders due to presence of melanocytes in other body districts, such as in the eyes, auditory, nervous and cardiac tissues, where melanocytes are thought to have roles different from that played in the skin. Several pathogenetic models have been proposed to explain vitiligo onset and progression, but clinical and experimental findings point mainly to the autoimmune hypothesis as the most qualified one. In this context, it is of relevance the strong association of vitiligo with other autoimmune diseases, in particular with autoimmune thyroid disorders, such as Hashimoto thyroiditis and Graves’ disease. In this review, after a brief overview of vitiligo and its pathogenesis, we will describe the clinical association between vitiligo and autoimmune thyroid disorders and discuss the possible underlying molecular mechanism(s).
2017
Autoimmune polyendocrine syndromes; Autoimmune thyroid diseases; CD8+ T cells; Reactive oxygen species; Thyroglobulin; TSH receptor; Tyrosinase; Vitiligo; Endocrinology, Diabetes and Metabolism
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Vitiligo and autoimmune thyroid disorders / Baldini, Enke; Odorisio, Teresa; Sorrenti, Salvatore; Catania, Antonio; Tartaglia, Francesco; Carbotta, Giovanni; Pironi, Daniele; Rendina, Roberta; D'Armiento, Eleonora; Persechino, Severino; Ulisse, Salvatore. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - STAMPA. - 8:(2017). [10.3389/fendo.2017.00290]
File allegati a questo prodotto
File Dimensione Formato  
Baldini_Vitiligo_2017.pdf

accesso aperto

Note: PDF
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 136.08 kB
Formato Adobe PDF
136.08 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1017965
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 34
social impact